19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Impaired White Matter Integrity for Depression in Parkinson'sHealth Tip: Fight Seasonal Affective DisorderNetwork Density Not Linked to Response in Teen DepressionSimple ECG May Help Distinguish MDD From Bipolar DepressionTreatment Trajectories Vary for Children With DepressionIf Dad Has Depression, Kids Might Develop It, TooPsychedelic Amazonian Drug Might Ease Symptoms of Depression, AlcoholismHelp for Seasonal DepressionOnline CBT Program Beneficial for Depression, AnxietyLocus ID'd That Links Comorbid Alcohol Dependence, DepressionSummer Baby, Higher Odds for Postpartum Depression?More Evidence That Depression Shortens LivesRegular Leisure-Time Exercise May Cut Incidence of DepressionMoving Just 1 Hour a Week May Curb Depression RiskHealth Tip: Do You Need Psychological Therapy?Psychosocial Intervention Ups Adherence to AntidepressantsPostpartum Depression Likely to Recur With Future PregnanciesCancer Patients May Have Undiagnosed DepressionMom-to-Be's Antidepressants Tied to Kids' Psychiatric WoesToo Many New Mothers Silent on Postpartum Depression1 in 5 Moms Mum About Post-Pregnancy BluesGoogle Search for 'Depression' Now to Provide Screening TestAre Depressed Teens Prone to Violence?Antidepressants Used by 12.7 Percent of Those Age ≥12 in U.S.U.S. Antidepressant Use Jumps 65 Percent in 15 YearsSmoking During Pregnancy Up Among Women With DepressionDepression After Coronary Artery Disease Diagnosis Ups Death RiskYoga May Help Ease DepressionToo Soon to Widely Recommend Ketamine for DepressionLonger Estrogen Exposure May Protect Against DepressionEstrogen May Influence Women's Depression RiskLosing Medicaid Tough on People Battling Depression: StudyLink for Maternal Antidepressant, Kids' Brain Health QuestionedAddition of Aripiprazole Ups Major Depressive Disorder RemissionNo Sign That Antidepressants in Pregnancy Harm Kids' Brains: StudyMed Switch Not Always Best Choice With Tough DepressionDepression Contributes to Health Decline Seen in Cancer CaregiversDepression May Worsen Health for Cancer CaregiversElectric Brain Stimulation No Better Than Meds For Depression: StudyDepression Inversely Linked to Body Composition in TeensReview: Depression Screening As Inpatient Important, FeasibleDepression Can Slow Hospital Patients' Recovery: StudyAntidepressants During Pregnancy Safe for Baby: StudyChronic Pain Common in Adults With Depression, AnxietyWhat You Need to Know About AntidepressantsAPA: Internet-Based CBT Can Be Helpful in DepressionCan Online Treatment Replace Your Therapist?Depression Often a Precursor to Falls in Elderly PeopleOverweight in Childhood May Up Lifetime Risk of DepressionHeavy Kids Face Triple the Odds for Depression in Adulthood
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Obesity, Sex Predict Remission for Antidepressant Medications


HealthDay News
Updated: May 4th 2017

new article illustration

THURSDAY, May 4, 2017 (HealthDay News) -- Obesity and sex are differential predictors of acute remission for commonly used antidepressant medications, according to a study published in the March-April issue of Personalized Medicine in Psychiatry.

Erin Green, Ph.D., from the VA Palo Alto Health Care System in California, and colleagues obtained data for 659 outpatients (ages 18 to 65 years) who completed the iSPOT-D practical randomized controlled trial. The patients were classified as normal-weight, overweight, or obese, based on World Health Organization criteria (42, 28, and 31 percent, respectively). Participants were randomized to eight weeks of escitalopram, sertraline, or venlafaxine extended-release (venlafaxine-XR) and were then categorized as remitters or non-remitters.

The researchers found that body mass index (BMI) was a differential predictor of remission based on antidepressant type. Compared with normal-weight patients, morbidly obese patients were more likely to remit on venlafaxine-XR; the effect was driven by a decline in physical symptoms, including sleep disturbance, somatic anxiety, and appetite. To achieve remission with venlafaxine-XR in obese III participants, the number needed to treat was six. Females, but not males, with higher BMI were more likely to remit, irrespective of medication type; the effect correlated with change in cognitive symptoms, including suicidal ideation, guilt, and psychomotor changes.

"Our findings suggest that considering BMI and sex, and assessing specific symptoms, could help tailor antidepressant choices to improve remission from depression in specialty and primary care settings," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry; one author disclosed ties to the health insurance industry and to Brain Resource Ltd., which supported iSPOT-D.

Abstract
Full Text